Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

Sreenath V. Sharma, Daphne W. Bell, Jeffrey Settleman, Daniel A. Haber, Epidermal growth factor receptor mutations in lung cancer Nature Reviews Cancer. ,vol. 7, pp. 169- 181 ,(2007) , 10.1038/NRC2088

Xiao-Feng Zheng, David Fiorentino, Jie Chen, Gerald R. Crabtree, Stuart L. Schreiber, TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin Cell. ,vol. 82, pp. 121- 130 ,(1995) , 10.1016/0092-8674(95)90058-6

B. B. Friday, A. A. Adjei, Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy Clinical Cancer Research. ,vol. 14, pp. 342- 346 ,(2008) , 10.1158/1078-0432.CCR-07-4790

S. A. Perera, D. Li, T. Shimamura, M. G. Raso, H. Ji, L. Chen, C. L. Borgman, S. Zaghlul, K. A. Brandstetter, S. Kubo, M. Takahashi, L. R. Chirieac, R. F. Padera, R. T. Bronson, G. I. Shapiro, H. Greulich, M. Meyerson, U. Guertler, P. G. Chesa, F. Solca, I. I. Wistuba, K.-K. Wong, HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy Proceedings of the National Academy of Sciences of the United States of America. ,vol. 106, pp. 474- 479 ,(2009) , 10.1073/PNAS.0808930106

Lucia Regales, Marissa N. Balak, Yixuan Gong, Katerina Politi, Ayana Sawai, Carl Le, Jason A. Koutcher, David B. Solit, Neal Rosen, Maureen F. Zakowski, William Pao, Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLOS ONE. ,vol. 2, ,(2007) , 10.1371/JOURNAL.PONE.0000810

J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C.-M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley, P. A. Janne, MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Science. ,vol. 316, pp. 1039- 1043 ,(2007) , 10.1126/SCIENCE.1141478

Jeffrey A Engelman, Liang Chen, Xiaohong Tan, Katherine Crosby, Alexander R Guimaraes, Rabi Upadhyay, Michel Maira, Kate McNamara, Samanthi A Perera, Youngchul Song, Lucian R Chirieac, Ramneet Kaur, Angela Lightbown, Jessica Simendinger, Timothy Li, Robert F Padera, Carlos García-Echeverría, Ralph Weissleder, Umar Mahmood, Lewis C Cantley, Kwok-Kin Wong, Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers Nature Medicine. ,vol. 14, pp. 1351- 1356 ,(2008) , 10.1038/NM.1890

William Pao, Vincent A Miller, Katerina A Politi, Gregory J Riely, Romel Somwar, Maureen F Zakowski, Mark G Kris, Harold Varmus, Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain PLoS Medicine. ,vol. 2, pp. e73- ,(2005) , 10.1371/JOURNAL.PMED.0020073

Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram, Pasi A. Jänne, Olivier Kocher, Matthew Meyerson, Bruce E. Johnson, Michael J. Eck, Daniel G. Tenen, Balázs Halmos, EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib The New England Journal of Medicine. ,vol. 352, pp. 786- 792 ,(2005) , 10.1056/NEJMOA044238

Do-Hyung Kim, Dos D. Sarbassov, Siraj M. Ali, Jessie E. King, Robert R. Latek, Hediye Erdjument-Bromage, Paul Tempst, David M. Sabatini, mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery Cell. ,vol. 110, pp. 163- 175 ,(2002) , 10.1016/S0092-8674(02)00808-5